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A B S T R A C T
Hypoxia is a feature of many disease states where convective oxygen delivery is impaired, and is known to
suppress oxidative metabolism. Acclimation to hypoxia thus requires metabolic remodelling, however hypoxia
tolerance may be aided by dietary nitrate supplementation. Nitrate improves tissue oxygenation and has been
shown to modulate skeletal muscle tissue metabolism via transcriptional changes, including through the acti-
vation of peroxisome proliferator-activated receptor alpha (PPARα), a master regulator of fat metabolism. Here
we investigated whether nitrate supplementation protects skeletal muscle mitochondrial function in hypoxia and
whether PPARα is required for this effect. Wild-type and PPARα knockout (PPARα−/−) mice were supple-
mented with sodium nitrate via the drinking water or sodium chloride as control, and exposed to environmental
hypoxia (10% O2) or normoxia for 4 weeks. Hypoxia suppressed mitochondrial respiratory function in mouse
soleus, an effect partially alleviated through nitrate supplementation, but occurring independently of PPARα.
Specifically, hypoxia resulted in 26% lower mass specific fatty acid-supported LEAK respiration and 23% lower
pyruvate-supported oxidative phosphorylation capacity. Hypoxia also resulted in 24% lower citrate synthase
activity in mouse soleus, possibly indicating a loss of mitochondrial content. These changes were not seen,
however, in hypoxic mice when supplemented with dietary nitrate, indicating a nitrate dependent preservation
of mitochondrial function. Moreover, this was observed in both wild-type and PPARα−/− mice. Our results
support the notion that nitrate supplementation can aid hypoxia tolerance and indicate that nitrate can exert
effects independently of PPARα.
1. Introduction
Tissue hypoxia is a key feature of many pathologies, including
cardiovascular disease, respiratory diseases and many cancers [1], and
is also experienced by healthy individuals at high altitude. The phy-
siological response to hypoxia includes changes that improve con-
vective oxygen delivery [2], however it is increasingly recognised that
changes in oxygen utilisation at the tissue level can also occur. A fall in
the capacity for oxidative metabolism, including fatty acid oxidation,
occurs in the skeletal muscle of humans and rodents following pro-
longed exposure to hypoxia [3]. A purported key player in regulating
this response is peroxisome proliferator-activated receptor α (PPARα),
a transcriptional regulator of fatty acid metabolism in heart, liver and
skeletal muscle [4]. PPARα is downregulated in hypoxic cells under the
action of hypoxia-inducible factor 1 (HIF1) [5], whilst its expression
falls in lowlander muscle following acclimatisation to high altitude [6].
Meanwhile, in hypoxic rodent heart, the transcriptional response to
hypoxia includes downregulation of PPARα target genes, and a switch
in substrate preference away from fatty acid oxidation [7–10].
Such changes in oxidative metabolism may occur alongside an in-
creased reliance on glucose metabolism, including increased glycolysis
[11–13], potentially improving the efficiency of oxygen utilisation (ATP
produced per O2 consumed) and thereby matching tissue oxygen de-
mand to the diminished supply, but this may also limit the capacity for
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ATP synthesis. In hypoxic rats, metabolic changes were associated with
lower ATP levels in skeletal muscle, in comparison with normoxic rats
[14]. These changes, however, were prevented in rats that received a
moderate dose of sodium nitrate via the drinking water, protecting
muscle ATP levels [14].
Inorganic nitrate (NO3−) can be consumed by humans as part of a
normal, healthy diet with high levels present in green leafy vegetables
and beetroot [15]. At a whole body level, nitrate supplementation has
been shown to decrease the O2 cost of exercise in healthy subjects in
both normoxic and hypoxic conditions [16–20], in a clinical population
suffering from hypoxia as a result of chronic obstructive pulmonary
disease [21], and also in subjects with decreased O2 carrying capacity
due to blood donation [22].
Once consumed, nitrate is believed to be reduced in a stepwise
fashion, firstly to nitrite (NO2−) and then to nitric oxide (NO) [23, 24],
adding to the endogenous production of NO from the NO synthase-
dependent oxidation of L-arginine [25]. NO is a diatomic free radical
that acts as a signalling molecule and is regarded to be the chief med-
iator of the responses observed with nitrate supplementation [26]. NO
has been shown to exert numerous biological effects in relation both to
the delivery of O2, through the well characterised mediation of vascular
tone [27,28], and the utilisation of O2 through effects upon mi-
tochondrial function. Whilst some of the changes in tissue metabolism
exerted by NO may occur secondary to altered haemodynamic function
and improved O2 delivery [29], studies in cultured myocytes have
shown direct effects of nitrate supplementation on fatty acid metabo-
lism via activation of the PPAR family of transcription factors by cyclic
GMP (cGMP), a downstream mediator of NO activity. In vivo, nitrate
supplementation thereby enhanced fatty acid oxidation capacity and
mitochondrial content in the skeletal muscle of normoxic and hypoxic
rodents, lowering intramuscular levels of long-chain fatty acid inter-
mediates [14].
Elevated levels of NO metabolites have been seen in human popu-
lations native to high altitude regions in Tibet and the Andes [30–32],
with selection of genetic variants in NO synthase genes [33]. In parti-
cular, Tibetans have high levels of exhaled NO [34] and circulating NO
biomarkers, which are associated with enhanced forearm blood flow
[32]. The haemodynamic effects of elevated NO production may
therefore be protective at altitude, indeed in lowlanders circulating
levels of nitrate, nitrite and cGMP increased during acclimatisation
[35]. It is not clear though, whether the protective effects of nitrate on
mitochondrial function and other aspects of energy metabolism occur at
altitude, since PPARα expression and/or activity is downregulated in
hypoxic skeletal muscle [6,10]. Moreover, in one Tibetan population,
the Sherpa, selection for a variant in the gene encoding PPARα (PPARA)
is associated with a lower capacity for skeletal muscle fatty acid oxi-
dation compared with lowlanders, alongside improved mitochondrial
efficiency, lower levels of oxidative stress and protection of muscle
energetics at high altitude [6].
We therefore hypothesised that inorganic nitrate exerts protective
effects on skeletal muscle mitochondrial function in the context of hy-
poxia, independent of PPARα activation. To investigate this we em-
ployed an 8-arm study design, exposing wild-type or PPARα knockout
mice to normoxia or 10% hypoxia for four weeks, and supplementing
them with either a moderate dose of sodium nitrate (0.7 mM) or sodium
chloride (0.7 mM) as control. Mitochondrial respiratory function was
measured in saponin-permeabilised skeletal muscle fibres, whilst levels
of metabolic proteins and regulators were measured using im-
munoblotting.
2. Methods
Animal work was conducted in accordance with UK Home Office
regulations under the Animals in Scientific Procedures Act, and un-
derwent review by the University of Cambridge Animal Welfare and
Ethical Review Committee. Procedures involving live animals were
carried out by a licence holder in accordance with these regulations.
2.1. Study design
Mice were bred on a pure 129Ev/Sv background with 10 back-
crosses [7]. The original breeding pairs were a kind gift of Frank
Gonzalez (National Institutes of Health, Bethesda, MD). Male wild-type
129Ev/Sv (n=42) and constitutive PPARα−/− littermates (n=42)
were housed in conventional cages from birth in a temperature (23 °C)
and humidity controlled environment with a 12 h/12 h light/dark
cycle. Normoxic mice were housed under the same environmental
conditions as those mice in the hypoxia chamber. Mice were fed a
Fig. 1. Study design. Each stage took place within the ages shown±4 d, and the length of each stage was identical for each mouse. The left section represents wild-
type (PPARα+/+) mice and the right section represents PPARα knockout (PPARα−/−) mice. The number in brackets indicates the number of mice in each group.
Chloride (0.7 mM NaCl) in distilled water ad libitum; Nitrate (0.7 mM NaNO3) in distilled water ad libitum; Normoxia, 21% atmospheric O2; Hypoxia, 10% at-
mospheric O2. Background patterns reflect those used in box and whisker plots in subsequent figures.
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standardised quality-controlled diet (RM1(E)SQC), comprising 65.0%
carbohydrate, 13.1% crude protein, 3.5% crude fat, 10mg/kg nitrate,
trace nitrite (Special Diet Services, Witham, Essex, UK) and initially
provided with distilled water ad libitum.
The study design is outlined in Fig. 1. At 6 weeks of age, mice from
both genotypes were randomly assigned to receive drinking water
supplemented either with 0.7mM sodium nitrate (NaNO3) or 0.7mM
sodium chloride (NaCl) for the remainder of the study. NaCl was used to
control for any effects of sodium intake. A concentration of 0.7 mM was
chosen as this has been shown to increase plasma and tissue levels of
nitrogen oxides in mice [36].
One week following the initiation of sodium nitrate or sodium
chloride treatment, mice were randomly assigned either to remain
under normoxic conditions (21% O2) or to be housed in hypoxia (10%
O2) in a chamber (PFI Systems Ltd., Milton Keynes, UK). Mice remained
in these conditions for four weeks. Nitrate treatment was thus initiated
1 week prior to hypoxic exposure in order to achieve stable circulating
nitrogen oxide levels. Body mass, food and water intake were measured
upon initiation of treatment, and thence weekly.
Mice were killed 80 ± 4 days after birth by dislocation of the neck.
From each mouse, one soleus was excised and immediately placed in ice
cold biopsy preservation solution (BIOPS), comprising 2.77mM
CaK2EGTA, 7.23mM K2EGTA, 6.56mM MgCl2.6H2O, 20mM taurine,
15 mM phosphocreatine, 20mM imidazole, 0.5mM dithiothreitol,
50 mM MES, 5.77mM Na2ATP, pH 7.1 [10] for respirometry experi-
ments (Section 2.2). Following this, the muscle fibre bundles were re-
covered from the Clark electrode chambers and homogenised for citrate
synthase activity quantification (Section 2.3) and determination of
myosin heavy chain isoform composition via SDS-PAGE (Section 2.4).
The second soleus was snap-frozen in a cryovial under liquid nitrogen
for western blotting to assess metabolic proteins (Section 2.5). A drop of
blood taken from the tail vein was loaded into a microcuvette and
haemoglobin concentration analysed using a HemoCue Hb201 Analyzer
(Quest Diagnostics, Sweden).
2.2. Measurement of mitochondrial respiratory function
Soleus muscle fibre bundles were permeabilised using saponin as
previously described [37]. Respirometry was carried out at 37 °C using
a Clark-type oxygen electrode and a water-jacketed chamber with
constant stirring (Strathkelvin Instruments, Motherwell, UK). Respira-
tion rates were analysed using two substrate/inhibitor assays with each
assay run in duplicate. In Assay 1, flux through the N-pathway via
electron transfer system complex I was assessed initially in the LEAK
state in response to the addition of 2mM malate plus 10mM glutamate
(GML), with OXPHOS being subsequently being stimulated through the
addition of 10mM ADP (GMP). In order to inhibit complex I, 0.5 μM of
rotenone was then added, followed by the addition of 10mM succinate
to assess flux through the S-pathway via complex II (SP). In Assay 2,
fatty acid oxidation capacity was assessed initially in the LEAK state
through the addition of 2mM malate plus 40 μM palmitoyl-carnitine
(PalML). Following this, oxidative phosphorylation (OXPHOS) was sti-
mulated through the addition of 10mM ADP (PalMP) and carbohydrate
oxidation was assessed through the addition of 5mM pyruvate (PMP).
Oxygen consumption was normalised to the wet weight of tissue used
(approximately 0.5–1.5 mg per assay).
2.3. Citrate synthase activity assay
Following respirometry, the contents of the chamber were extracted
and homogenised using a Polytron (PT-10-35 GT Kinematic Inc.,
Switzerland) at 25,000 rpm for 30 s, with the addition of 1% Triton-
×100 and 10mg/ml protease inhibitor (Complete Protease Inhibitor
Cocktail, Roche). Protein content of whole soleus muscle homogenates
was assessed using Pierce BCA Protein Assay Kit (Thermo Scientific),
with subsequent detection performed using a Nanodrop 2000
spectrophotometer (ThermoFisher Scientific).
Citrate synthase activity was quantified on the resulting homo-
genate at 37 °C as described previously [38, 39]. The assay buffer
contained 20mM Tris, 0.1 mM, 5,5′-dithiobis2-nitrobenzoicacid and
0.3 mM of acetyl CoA at pH 8.00. The reaction was initiated by the
addition of 0.5mM oxaloacetate and absorbance change at 412 nm was
measured (Evolution 220, Thermo Scientific).
2.4. SDS-polyacrylamide gel electrophoreisis (PAGE) for soleus myosin
heavy chain isoform composition
The homogenate was spun using a microcentrifuge for 10min at
13,000 rpm. This was re-suspended in Laemmli sample buffer [40] at a
concentration of 40 μl/mg protein.
Gels were cast in vertical slab mini-gel plates with a thickness of
0.75mm. The separating gel, left to set at room temperature overnight,
comprised 30% glycerol, 4% acrylamide-N-N′-methylene-bis-acryla-
mide (bis) (50:1), 0.2M Tris (pH 8.8), 0.1 M glycine and 0.4% SDS. To
prevent drying, 10% Sodium Dodecyl Sulphate (SDS) was sprayed and
cling film wrapped around the top of the plates. This was removed prior
to the addition of the stacking gel, which comprised 30% glycerol, 4%
acrylamide-bis (50:1), 70 mM Tris (pH 6.7), 100mM EDTA (pH 7.0),
0.4% SDS. A 0.75mm 10-well spacer was inserted into the stacking gel
immediately after pouring. This was left to set for 1 h before the spacer
was removed and loading of the samples commenced. The pH of the
stock solutions for both separating and stacking gels was not adjusted
after these solutions were mixed. Polymerization of both gels was in-
itiated with 0.05% of NNN'N′-Tetramethylethylenediamine (TEMED)
and 0.1% ammonium persulfate (APS).
The gels were run utilising the Mini-PROTEAN II Cell set up (Bio-
Rad Laboratories). Upper running buffer, consisting of 50mM Tris,
75mM glycine, 0.05% SDS and 0.1% β-mercaptoethanol, was added to
the space between the two gels. Lower running buffer, containing the
same constituents as the upper buffer minus β-mercaptoethanol, was
added to the tank. A molecular weight marker 7 μL (Precision Plus
Protein™ Kaleidoscope™, Bio-Rad) was loaded alongside 13 μL of
muscle sample. The gel was then run at ~4 °C for 24 h at a constant
current of 4mA (PowerPack 300, Bio-Rad Laboratories).
Following completion of the SDS-PAGE run, the stacking gel was
removed and the separating gel washed in ddH2O. In order to visualise
and analyse the protein bands, the mini gel was stained with 20ml
Coomaisse®G250 stain, SimplyBlue™ Safestain (Invitrogen), for 1 h on a
rocker. It was then washed in 100ml ddH20 for 1 h prior to scanning
using a HP Scanjet 3500c Series. The bands corresponding to myosin
heavy chain isoforms, located between 150 and 250 kDa, were analysed
by gel densitometry using ImageJ. From this, the proportion of type 1
and 2 fibres in each soleus sample was assessed.
Due to the inherent differences in fibre composition, extensor di-
gitorum longus (EDL) muscle was used as a control comparison to the
soleus. This was dissected from 3month old female wild type Parkes
wild type strain (PKS) mice, donated by Malcolm Logan (King's College
London). Wet weight was obtained and sample buffer added with a
minimum of 500 μl being required for homogenisation using a
gentleMACS dissociator (Miltenyi Biotech).
2.5. Western blotting for soleus metabolic proteins
Whole frozen soleus was powdered and then homogenised as de-
scribed previously [41]. For all antibodies excluding OXPHOS (see
below), samples were boiled prior to loading. Western blotting was
conducted as described previously [41]. The antibodies used were:
Total OXPHOS rodent WB antibody cocktail (OXPHOS) (ab110413,
Abcam), Anti-citrate synthase (CS) (SAB2701077, Sigma), mitofusin 2
(MFN2) (Cell Signalling 9482), PGC1α (AB3242, Millipore), long chain
acyl coA dehydrogenase (LCAD, a gift from Prof. Jerry Vockley, Uni-
versity of Pittsburgh [42]), carnitine palmitoyltransferase (CPT) 1
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(CPT1MIIA, Alpha Diagnostics) and pyruvate dehydrogenase kinase 4
(PDK4, a gift from Prof. Grahame Hardie, University of Dundee [43]).
All primary antibodies were diluted 1:1000, with the exception of
LCAD, which was diluted 1:5000. Secondary antibodies were diluted
1:10,000 and were as follows: Rabbit anti-mouse IgG (Pierce #31457),
rabbit anti-sheep IgG (Pierce #31480), goat anti-rabbit (Pierce
#31460). Immmobilon western chemiluminescent HRP substrate
(Merck Millipore) was used to quantify protein content after IgG
binding, and visualized on a G:BOX Chemi XT4 imager using GeneSys
capture software (Syngene, Cambridge, UK). Density of bands corre-
sponding to the target protein were corrected to the loading control
(mouse gastrocnemius) for that blot as well as the corresponding actin
band derived from Ponceau S staining.
2.6. Statistics
A three-way ANOVA was performed to assess the effects of hypoxia,
nitrate and PPARα, as well as the interactions between these factors.
The statistical approach has been described previously [44]. Initially a
three-way interaction was considered for significance. If a significant
three-way interaction was found, main effects and two-way interactions
were disregarded and a post-hoc Tukey's HSD (honest significant dif-
ference) test performed. Pairwise comparisons of groups between which
only one of the independent variables differed were considered, and the
results recorded. If the three-way interaction was not significant, a post-
hoc Tukey's HSD test was performed to investigate each two-way in-
teraction. Any main effects of variables involved in the significant two-
way interaction(s) were not considered, while main effects of variables
not involved in significant interactions were. In instances where no
three-way or two-way interactions were significant, the main effects of
all three independent variables were considered. Main effects combine
all four groups in each state of one independent variable and make a
pairwise comparison between those combinations (e.g. all four hypoxic
vs all four normoxic groups). All analyses were performed using R
software (R Foundation for Statistical Computing). Differences were
considered statistically significant when P < 0.05.
Graphs were generated using Graphpad Prism 7 software and follow
a colour/pattern scheme whereby white indicates normoxia (21% O2),
blue hypoxia (10% O2), block colour chloride (Cl−) and striped nitrate
(NO3−) treated groups. In addition, the wild type (PPARα+/+) are
separated from the knockout (PPARα−/−). The majority of the data
(with the exception of body weights and MyHC isoform composition) is
shown as minimum to maximum box and whisker plots, with the
middle line representing the median and the box the interquartile range
(25th to 75th percentiles), so that the full data spread can be visualized.
Significant differences are indicated with black asterisks highlighting
interactions between genotypes (PPARα−/− vs PPARα+/+), blue as-
terisks highlighting interactions linked to O2 state (hypoxia vs nor-
moxia) and orange asterisks highlighting interactions linked to treat-
ment group (nitrate vs chloride).
3. Results
3.1. Body weights, food, water and nitrate intake and circulating
haemoglobin
Body weights were recorded on the first day of each week (Fig. 2A).
At the initiation of supplementation with sodium chloride or sodium
nitrate (Week 1), body weights did not differ between the chloride-fed
and nitrate-fed groups, nor between normoxic and hypoxic groups.
However, PPARα−/− mice were 6% lighter than wild-type mice
(P < 0.001, PPARα main effect). After one week, and just prior to
initiation of normoxic or hypoxic exposure (Week 2), body mass did not
differ between the mice that would be exposed to normoxia or those
that would be exposed to hypoxia. At this time-point, nitrate-treated
mice were 4% lighter than chloride-treated mice (P < 0.05, nitrate
main effect). After one week of exposure to normoxia or hypoxia (Week
3), hypoxic mice were 5% lighter than normoxic mice (P < 0.001,
hypoxia main effect), but neither PPARα nor nitrate treatment had any
effect on body weight at this time-point. At the end of the study (Week
6), hypoxic mice remained 4% lighter than normoxic mice (P < 0.001,
hypoxia main effect). In addition, PPARα−/− mice were 5% lighter
than wild-type mice (P < 0.01, PPARα main effect), and nitrate-
treated mice were 3% lighter than chloride-treated mice (P < 0.05,
nitrate main effect).
Neither treatment with nitrate, nor PPARα−/− had any effect on
food intake at any time-point, nor did they interact with any other
factor (Supplementary Fig. 1). In Week 1, food intake was similar be-
tween all groups. In the first week of hypoxic exposure (Week 2),
however, food intake of hypoxic mice was 34% lower than in normoxic
mice (P < 0.001, hypoxia main effect). This difference in food intake
persisted in week 3 (10% lower intake, P < 0.001, hypoxia main ef-
fect) and week 4 (8% lower intake, P < 0.001, hypoxia main effect),
but food intake was the same in all groups by week 5. Water intake was
similar between all groups in Weeks 1, 3, 4 and 5. In Week 2, however
(the first week of hypoxic exposure) water intake was 30% lower in
hypoxic mice compared with normoxic mice (P < 0.001, hypoxia main
effect) and 10% lower in PPARα−/− mice compared with wild-types
(P < 0.05, PPARα main effect).
Over the course of the study, nitrate intake from food and water was
8.8-fold higher in nitrate-treated mice compared with chloride-treated
mice (P < 0.001, nitrate main effect, Fig. 2B). In Week 2, total nitrate
intake was decreased by 6% by hypoxic exposure in the nitrate-fed
hypoxic mice (P < 0.001, Tukey's test of nitrate/hypoxic interaction)
owing to the acute effect of hypoxic exposure on water intake, however
water intake and thus nitrate intake was restored in these mice by Week
3.
Blood haemoglobin concentration [Hb], measured at the end of the
study, was 85% higher in hypoxic mice than in normoxic mice
(P < 0.001 hypoxia main effect, Fig. 2C).
3.2. Myosin heavy chain isoform composition and mitochondrial
morphology
We sought to understand the effects of PPARα, nitrate-supple-
mentation and hypoxic exposure, and any interactions between these
factors, on relative expression of myosin heavy chain (MyHC) isoforms
and mitochondrial biogenesis, dynamics and content. Relative expres-
sion of MyHC isoforms, suggested that hypoxic exposure induced a
fibre-type shift in soleus towards a faster phenotype, with a 34% greater
type II isoform expression compared with normoxic mice (P < 0.01,
hypoxia main effect, Fig. 3A). Protein levels of peroxisome proliferator-
activated receptor γ co-activator 1α (PGC1α), a master regulator of
mitochondrial biogenesis, were 20% lower in PPARα−/− mice com-
pared with wild-types (P < 0.05, PPARα main effect, Fig. 3B), high-
lighting an effect of PPARα on PGC1α expression with no significant
changes due to nitrate or hypoxia. Protein levels of mitofusin 2 (MFN2),
a mediator of fusion between mitochondrial outer membranes, were the
same in all mice (Supplementary Fig. 2).
Citrate synthase activity is a candidate marker of muscle mi-
tochondrial density [45]. Activity of citrate synthase was 24% lower in
the hypoxic chloride-treated mice compared with normoxic chloride-
treated mice (P≤ 0.01), however there was no difference in soleus ci-
trate synthase activity between normoxic and hypoxic mice when
treated with nitrate (Fig. 3C). Moreover, citrate synthase activity was
18% lower in the soleus of chloride-treated PPARα−/− mice compared
with that of chloride-treated wild-type mice, however no difference was
seen between the PPAR−/− and wild-type mice treated with nitrate.
Thus, both hypoxia and PPARα knockout had a negative impact on
soleus citrate synthase activity, but this was prevented by nitrate sup-
plementation.
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Fig. 2. Body weights, nitrate intake and circulating haemoglobin. A) Body weights (n=10–12 per group) on the first day of the week indicated, with dietary nitrate
supplementation beginning on week 1 and hypoxic treatment beginning on week 2. Data represented as mean ± SEM. B) Cumulative nitrate (NO3−) intake from
food and water throughout the study. C) Haemoglobin concentration (g/L), immediately after sacrifice. Data are represented as minimum to maximum values,
n= 6–12 per group. ***P < 0.001 nitrate effect (orange) or hypoxia effect (blue).
Fig. 3. Soleus muscle morphology and mitochondrial markers. A) Myosin heavy chain isoform type proportions, B) PGC1α protein levels, C) Citrate synthase activity
in mouse soleus. Data presented as mean ± SEM in graph A and as minimum to maximum values in graphs B and C, n= 5–10 per experiment group. *P < 0.05,
**P < 0.01 genotype effect (black) or hypoxia effect (blue).
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3.3. Mitochondrial respiratory function
Mitochondrial respiratory capacity was assessed in saponin-per-
meabilised soleus muscle fibres using two assays that employed sub-
strate/inhibitor combinations to probe respiration under different
coupling states and via different substrate-led pathways.
In the first assay, substrates for the N-pathway via Complex I and S-
pathway via Complex II, were used to probe the effects of PPARα, ni-
trate-supplementation and hypoxia on the electron transfer system
(ETS). LEAK state respiration in the presence of glutamate and malate
(N-pathway via Complex I) was 12% lower in PPARα−/− compared
with wild-type mice (P≤ 0.05, PPARα main effect, Fig. 4A), whilst
neither nitrate nor hypoxia affected this. OXPHOS state respiration with
glutamate and malate, was similar across all experimental groups
(Fig. 4B). OXPHOS capacity in the presence of succinate and rotenone
(S-pathway via Complex II) was 14% lower in hypoxic mice compared
with normoxic mice (P < 0.01, hypoxia main effect, Fig. 4C). Thus,
LEAK state respiration was suppressed by PPARα knockout, whilst
OXPHOS respiration via the S-pathway was suppressed by hypoxia
possibly due to a hypoxia-induced attenuation of Complex II activity.
In the second assay of mitochondrial respiratory function, fatty acid
oxidation capacity was assessed in LEAK and OXPHOS states using
palmitoyl-carnitine and malate as substrates, before pyruvate was
added as a substrate for the N-pathway via Complex I. PPARα−/− re-
sulted in 10% lower LEAK state respiration (P < 0.05, PPARα main
effect, Fig. 5A), though OXPHOS respiration was not affected (Fig. 5B).
LEAK state respiration with palmitoyl-carnitine and malate was 26%
lower in chloride-treated hypoxic mice compared with normoxic mice,
but nitrate-supplementation prevented this (P < 0.001, Tukey's test of
nitrate/hypoxia interaction, Fig. 5A). OXPHOS respiration supported by
palmitoyl-carnitine was 15% lower in hypoxic mice compared with
normoxic mice (P < 0.01, hypoxia main effect) and this was un-
affected by nitrate treatment (Fig. 5B). OXPHOS respiration supported
by pyruvate was 24% lower in chloride-treated hypoxic mice compared
with normoxic mice (P < 0.001), however this was not seen in hypoxic
mice supplemented with nitrate (Tukey's test of nitrate/hypoxia inter-
action, Fig. 5C). Taken together, these data suggest that (i) hypoxia
lowers mitochondrial oxidation capacity for fatty acids and pyruvate,
(ii) dietary nitrate prevents the hypoxic-induced decline in pyruvate
(though not fatty-acid) oxidation, and (iii) these effects occur in a
PPARα-independent manner.
3.4. Expression of fatty acid oxidation enzymes
Finally, to further understand the PPARα-dependent effects of hy-
poxic exposure and nitrate supplementation on fatty acid and pyruvate
oxidation we looked at expression of some key metabolic mediators.
Levels of long chain acyl CoA dehydrogenase (LCAD) were 16% lower
in PPARα−/− mice compared with wild-type mice (P < 0.05, PPARα
main effects, Fig. 6A). Similarly, protein levels of carnitine palmitoyl-
transferase 1 (CPT1) were 17% lower in PPARα−/− mice compared
with wild-type mice (P < 0.05, PPARα main effects, Fig. 6B). In ad-
dition, across both genotypes CPT1 levels were 17% lower in hypoxic
mice compared with normoxic mice (P≤ 0.05). These changes in levels
of proteins regulated by PPARα were unaffected by nitrate treatment.
Despite the effect of hypoxia on pyruvate-supported OXPHOS, and the
counteracting effect of nitrate-supplementation, there were no differ-
ences in the levels of the regulatory protein pyruvate dehydrogenase
J
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Fig. 4. Mitochondrial respiratory capacities. A) LEAK state respiration (JO2) through the N-pathway via Complex I with malate and glutamate (GML). B) OXPHOS
state respiration (JO2) through the N-pathway via Complex I with malate, glutamate and ADP (GMP). C) OXPHOS state respiration (JO2) through the S-pathway via
Complex II with succinate and rotenone (SP). Respiration rates are corrected to mass of soleus muscle fibres. Data are represented as minimum to maximum values,
n= 6–10 per experiment group. *P < 0.05, **P < 0.01 genotype effect (black) or hypoxia effect (blue).
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kinase 4 (PDK4) between the groups (Supplementary Fig. 3).
4. Discussion
In the context of chronic tissue hypoxia, oxidative metabolism is
suppressed [3], thereby matching tissue oxygen demand to the dimin-
ished supply. A key player in this response in a number of tissues is
PPARα [5,7,8,10], a master regulator of fatty acid oxidation [4].
Dietary supplementation with inorganic nitrate exerts haemodynamic
effects [29] which can improve tissue oxygenation, and alleviated the
metabolic consequences of hypoxia in the rat heart [46]. Nitrate also
stimulates oxidative metabolism in skeletal muscle, acting via PPARα
[14], therefore we sought to investigate whether the protective effects
of nitrate in the context of hypoxia were independent of PPARα.
In mouse soleus, hypoxia was associated with a fibre-type switch
towards fast contracting fibres, with no effect of nitrate or PPARα ex-
pression. Citrate synthase activity was lower in the soleus with hypoxia
and also with PPARα−/−, but in both cases this was prevented by
dietary nitrate. Regarding mitochondrial respiration, LEAK state re-
spiration with glutamate and malate and OXPHOS respiration with
succinate were suppressed in hypoxic soleus. Meanwhile, fatty acid and
pyruvate oxidation capacities were lower in hypoxic soleus, whilst
J
L
J
P
J
P
Fig. 5. Mitochondrial fatty acid and pyruvate oxidation capacities. A) LEAK state respiration (JO2) with malate and palmitoyl carnitine (PalML). B) OXPHOS state
respiration (JO2) with malate and palmitoyl carnitine (PalMP). C) OXPHOS state respiration (JO2) through the N-pathway via Complex I with malate and pyruvate
(PMP). Respiration rates are corrected to mass of soleus muscle fibres. Data are represented as minimum to maximum values, n=6–10 per experiment group.
*P < 0.05, **P < 0.01, ***P < 0.001 genotype effect (black) or hypoxia effect (blue).
Fig. 6. Fatty acid oxidation enzyme protein levels. A) Levels of long chain acyl CoA dehydrogenase (LCAD) and B) carnitine palmitoyltransferase protein in soleus
muscle. Data are represented as minimum to maximum values, n=3–5 per experiment group. *P < 0.05 genotype effect (black) or hypoxia effect (blue).
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nitrate reversed the hypoxia-induced decline in pyruvate (though not
fatty-acid) oxidation. These effects on fatty acid and pyruvate oxidation
occurred in a PPARα-independent manner. As expected, protein levels
of LCAD and CPT1 were lower in PPARα−/− mice compared with wild-
types, but CPT1 levels were also lower in hypoxic mice across both
genotypes, with no effect of nitrate treatment.
The complex study design allowed us to probe the interaction be-
tween the three factors, whilst addressing the core question of whether
PPARα is necessary for the protective effects of nitrate on metabolism
in hypoxic muscle. Central to this study was the statistical approach,
which permitted us to examine interactions between nitrate, hypoxia
and PPARα expression, and address the main hypothesis [44]. The
three-way ANOVA represented a relatively conservative approach, and
may have resulted in type II errors, particularly when considering the
effect of a single stressor on an outcome, e.g. the effect of PPARα
knockout on mitochondrial fatty acid oxidation capacity. Prior to
commencing the study, we considered an alternative approach of se-
parately examining wild-type and PPARα−/− mice using two two-way
ANOVAs, but rejected this approach because it fails to test the main
hypothesis.
As with our previous studies [14,46], the precise control of nitrate
intake was achieved with the use of a standardised quality-controlled
diet and deionised water. A possible confounding factor was the ne-
gative effect of hypoxia on food and water intake, and thus body
weight. This was most pronounced during the first week of hypoxic
exposure, with water intake returning to normal in the second week and
food intake recovering to match that of normoxic mice by the final
week. The relatively long duration of the study was therefore a
strength, since stabilisation of water intake meant that nitrate intake
was identical between the supplemented groups for the final three
weeks. A possible limitation of this study is the exclusive use of male
mice, indeed dimorphic differences in the response to nitrate supple-
mentation have been noted in human subjects [47]. Finally, our pre-
vious studies on nitrate supplementation in hypoxia have largely used
rats, owing to the similarity in NO production rates [48] and circulating
nitrate/nitrite levels between rats and humans [49], however it was
necessary to use genetically-manipulated mice in this study in order to
understand the role of PPARα.
In agreement with previous work on human muscle from our lab
[6], hypoxia elicited metabolic responses in mouse soleus consistent
with a decreased capacity for oxidative metabolism. The relative switch
in abundance of myosin heavy chain isoforms away from type I MyHC
towards type II MyHC, is consistent with a preference for glycolytic
energy metabolism over oxidative phosphorylation, and this was par-
alleled by a lower activity of citrate synthase in hypoxic mouse soleus.
Citrate synthase is a purported marker of mitochondrial content in
human skeletal muscle [45], and fell in the muscle of lowlanders during
an ascent of Everest alongside a loss of mitochondrial volume density
[50]. Citrate synthase activity was also lower in the soleus of PPARα−/
− mice compared with wild-type mice. There was no difference in le-
vels of PGC1α between hypoxic and normoxic mice though, suggesting
that any changes in mitochondrial abundance in this study were not as
a result of decreased PGC1α expression.
Further effects of hypoxia on oxidative metabolism were seen upon
examination of mitochondrial respiratory capacity, including decreased
OXPHOS respiration per unit mass of tissue in the presence of succinate
(S-pathway via complex II), palmitoyl-carnitine and pyruvate, and
lower LEAK state respiration with palmitoyl-carnitine. In previous
studies from our group on rat soleus, we did not see any effect of hy-
poxia on mass-corrected respiration rates in permeabilised fibres de-
spite some changes in metabolic gene expression, enzyme activities and
muscle metabolite concentrations [10,14]. This may highlight a dif-
ference in the effect of hypoxia on rats and mice, but may have been
due to the shorter duration of hypoxic exposure used previously
(2 weeks). The lower respiratory rates we report here in hypoxic mouse
soleus may have resulted from a loss of mitochondrial content per se, as
suggested by lower citrate synthase activities. Succinate-supported
OXPHOS capacity also fell in the muscle of lowlanders acclimatising to
high-altitude though [6], whilst protein levels of succinate dehy-
drogenase were seen in a separate group of subjects undertaking the
same ascent to Everest Base Camp [51]. Meanwhile, octanoyl-carnitine
supported respiration rates declined in the muscle of lowlanders at
high-altitude [6]. Moreover, in the present study protein levels of CPT1
were found to be lower in hypoxic mouse muscle than in normoxic
mice, perhaps contributing to a lower fatty acid oxidation capacity,
whilst CPT1B expression fell in human muscle at altitude [6]. Expres-
sion of CPT1B is controlled by PPARα, and our results may indicate a
hypoxia-driven suppression of PPARα transcriptional activity, although
notably in the present study hypoxic exposure resulted in lower CPT1
levels in both wild-type and transgenic mice, in addition to the negative
effect of PPARα knockout.
In line with our hypothesis, dietary supplementation with inorganic
nitrate elicited protective effects on metabolism in hypoxic mouse so-
leus independently of PPARα. The hypoxia-driven effects of lower ci-
trate synthase activity and lower mitochondrial respiration rates (LEAK
rate with palmitoyl-carnitine and OXPHOS rate with pyruvate) were
prevented in nitrate-supplemented mice irrespective of genotype.
However, it should be noted that not all effects of hypoxia were pre-
vented by nitrate supplementation in this study, perhaps owing to the
severity of the hypoxic exposure used here in comparison with previous
studies [14,46]. Mechanistically, nitrate is known to exert effects on
tissue oxygen delivery through its role as a vasodilator [27,28], and
improvements in tissue oxygenation via enhanced blood flow may un-
derpin the PPARα-independent effects reported here. In addition, ni-
trate exerts effects on skeletal muscle metabolism via other transcrip-
tion factors, including PPARβ/δ [14]. Indeed, it has been suggested that
high levels of expression of PPARβ/δ compensate for the loss of PPARα
in the skeletal muscle of PPARα−/− mice [52], and this may explain
why mitochondrial fatty acid oxidative phosphorylation capacities were
not lower in PPARα−/− mice compared with wild-type mice in this
study. Moreover, the activation of PPARα expression by nitrate is
brought about by the sequential reduction of nitrate to nitrite and NO
and thence the production of cGMP at the tissue level. cGMP also acts a
mediator in the downstream cellular response to natriuretic peptides,
eliciting numerous metabolic effects, many of which are independent of
PPARα [53]. For instance, cGMP is known to promote mitochondrial
biogenesis in skeletal muscle, acting via PGC1α [54]. Since PGC1α le-
vels were unaffected in mouse muscle by hypoxia or by ablation of
PPARα, it is possible that prevention of the hypoxia driven loss of ci-
trate synthase activity seen here was a result of PGC1α activation by
cGMP, brought about via improved NO availability.
5. Conclusions
In conclusion, dietary nitrate is able to exert effects on skeletal
muscle metabolism that counteract the effect of hypoxia, and this oc-
curs independently of PPARα. Our work may hold implications for the
use of nitrate in the treatment of diseases in which hypoxia is a factor
and in which PPARα expression and/or transcriptional activity is at-
tenuated. Moreover, our work suggests nitrate supplementation might
offer benefits to lowlander subjects at high-altitude, in whom PPARα
transcriptional activity is suppressed [6], and suggests that the high
circulating nitrogen oxide levels seen in some Tibetan populations
[32,34] might offer metabolic benefits despite lower PPARα expression
in the muscles of some groups, e.g. the Sherpa [6].
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbadis.2018.07.027.
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